Long-term results after resection for bone sarcoma pulmonary metastases

Area of Science:

• Oncology
• Surgical Oncology
• Pulmonary Medicine

Background:

• Pulmonary metastases from bone sarcomas affect approximately 40% of patients.
• Standard treatment combines chemotherapy and surgical resection.
• Identifying prognostic factors is crucial for improving long-term survival.

Purpose of the Study:

• To investigate prognostic factors influencing long-term survival in patients with bone sarcoma lung metastases.
• To evaluate the impact of various clinical, demographic, and treatment variables on overall survival.

Main Methods:

• Retrospective review of 52 patients undergoing pulmonary metastasectomy for bone sarcoma.
• Analysis of clinical and demographic data, primary tumor characteristics, and metastatic disease features.
• Univariate (log-rank) and multivariate (Cox regression) analyses to identify significant prognostic factors.
• Kaplan-Meier estimation of 5-year survival rates.

Main Results:

• Median follow-up was 28 months, with a median survival of 27 months.
• Overall 3- and 5-year survival rates were 43% and 31%, respectively.
• Disease-free interval (DFI) between primary tumor treatment and first lung metastasectomy, and DFI between first and second lung surgeries (DFI2) were significant prognostic factors.
• Gender, primary tumor site, histology, surgical approach, number of nodules, and type of resection did not significantly impact survival.

Conclusions:

• Long-term survival following bone sarcoma lung metastasectomy is achievable and encouraging.
• Disease-free intervals (DFI and DFI2) are the primary determinants of long-term survival in this patient cohort.